Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
RECORDATI GROUP clinical trials
Part of CVC Capital Partners, which holds 46.82% as of 2025-03-18. Source
The registry lists 31 studies whose lead sponsor is RECORDATI GROUP or one of 5 companies grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Keep track of what changes. Save the RECORDATI GROUP studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to RECORDATI GROUP.
- RECORDATI GROUP21 studiesSame company
Something wrong?
- 3 studies →
- Casen Recordati S.L.2 studies →Acquired — became part of RECORDATI GROUP, Oct 21, 2013 · source ↗
Something wrong?
- Laboratorios Casen-Fleet S.L.U.2 studies →Acquired — became part of RECORDATI GROUP, Oct 21, 2013 · source ↗
Something wrong?
- 2 studies →
- Laboratoires Bouchara-Recordati1 study →Acquired
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 31 of 31.
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRecruitingNCT03708900Phase 2
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeNot yet recruitingNCT07247162Phase 4
- An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and PediatricsRecruitingNCT05040178
Sponsor listed in the registry: Recordati Rare Diseases · First submitted after Recordati Rare Diseases became part of RECORDATI GROUP
- Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods ApproachRecruitingNCT04176523
Sponsor listed in the registry: Recordati Rare Diseases · First submitted after Recordati Rare Diseases became part of RECORDATI GROUP
- Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)Not yet recruitingNCT05995834
- A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab BetaActive, not recruitingNCT04253015
- REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult PatientsCompletedNCT04276558Phase 2
- Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaActive, not recruitingNCT05928390Phase 2
- Cold Agglutinin Disease Real World Evidence RegistryActive, not recruitingNCT05791708
- Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an AmpuleCompletedNCT07312643Phase 1
- Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's SyndromeActive, not recruitingNCT05382156
- Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's SyndromeCompletedNCT05633953
- Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699CompletedNCT03606408Phase 2
- Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate CancerWithdrawnNCT03990194
- Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.CompletedNCT01793480Phase 3
- Real-life Observational Study of Cancer Pain Management With MethadoneCompletedNCT05265442
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCompletedNCT02310269
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4
- Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)CompletedNCT04125927Phase 3
Sponsor listed in the registry: Recordati Rare Diseases · First submitted after Recordati Rare Diseases became part of RECORDATI GROUP
- Cross-sectional, Non-randomized Observational Study to Assess the Frequency of Reduced Sodium Intake in the Primary Care Setting - LAXAPCompletedNCT06121583
Sponsor listed in the registry: Casen Recordati S.L. · First submitted after Casen Recordati S.L. became part of RECORDATI GROUP
- Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPHTerminatedNCT02003742Phase 3
- Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseaseTerminatedNCT04838860Phase 2
Sponsor listed in the registry: Recordati UK · First submitted before Recordati UK became part of RECORDATI GROUP
- SILtuximab in Viral ARds (SILVAR) StudyTerminatedNCT04616586Phase 3
Sponsor listed in the registry: Recordati UK · First submitted before Recordati UK became part of RECORDATI GROUP
- Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord InjuryCompletedNCT03482037Phase 1/2
- Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPHCompletedNCT03179670
Sponsor listed in the registry: Laboratoires Bouchara-Recordati · Laboratoires Bouchara-Recordati — acquired company within the RECORDATI GROUP group
- Evaluation of the Quality of Bowel Cleansing in a Real Clinical Practice SettingCompletedNCT02839824
Sponsor listed in the registry: Casen Recordati S.L. · First submitted after Casen Recordati S.L. became part of RECORDATI GROUP
- Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic HyperplasiaCompletedNCT01757769Phase 4
- Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With MenopauseStatus unknownNCT01116310Phase 4
Sponsor listed in the registry: Laboratorios Casen-Fleet S.L.U. · First submitted before Laboratorios Casen-Fleet S.L.U. became part of RECORDATI GROUP
- Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential HypertensionCompletedNCT01093807Phase 2
- Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.CompletedNCT01065857Phase 3
Sponsor listed in the registry: Laboratorios Casen-Fleet S.L.U. · First submitted before Laboratorios Casen-Fleet S.L.U. became part of RECORDATI GROUP
- Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPHCompletedNCT00359905Phase 3